14/08/2025
Mounjaro users, brace yourselves: prices are set to jump by 170% starting 1 Sept—
but NHS access stays unchanged. Is this just ‘fair global pricing’ or pressure applied at our expense? What are your plans if costs surge—stick, switch, seek support? And will the next newcomer, Retatrutide, be any better? Share your thoughts …
Mounjaro (tirzepatide) used for diabetes and weight-loss—from about £92–£122 per month to £133–£330, depending on dose. That’s up to a 170% hike in private pay pricing. The NHS price, however, remains protected under existing agreements.
Why the steep increase?
Eli Lilly initially priced Mounjaro lower in the UK to ensure fast NHS access. Now, they’re aligning it with European markets to ensure “fair global contributions to the cost of innovation.”

This move also follows pressure from the U.S. government. President Donald Trump has issued an executive order / MFN policy pushing pharma companies to lower drug prices in the U.S.—and raise them abroad to rebalance the system with US costs as high as $1600 per pen.
Will this price out those who need it the most? What do you think of the price increase? Comment below and let’s chat